{"id":"https://openalex.org/W2355867009","doi":"https://doi.org/10.1200/jco.2016.67.2774","title":"The Beginning of the End of Package Deal Therapy for Patients With High-Risk Neuroblastoma?","display_name":"The Beginning of the End of Package Deal Therapy for Patients With High-Risk Neuroblastoma?","publication_year":2016,"publication_date":"2016-05-10","ids":{"openalex":"https://openalex.org/W2355867009","doi":"https://doi.org/10.1200/jco.2016.67.2774","mag":"2355867009","pmid":"https://pubmed.ncbi.nlm.nih.gov/27161969"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2016.67.2774","doi":"https://doi.org/10.1200/jco.2016.67.2774","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2016.67.2774","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"editorial","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5038758227","display_name":"David Maxwell Barrett","orcid":"https://orcid.org/0000-0002-8302-3114","observed_orcids":["https://orcid.org/0000-0002-8302-3114"]},"institutions":[{"id":"https://openalex.org/I1335321130","display_name":"Children's Hospital of Philadelphia","ror":"https://ror.org/01z7r7q48","country_code":"US","type":"funder","lineage":["https://openalex.org/I1335321130"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David M. Barrett","raw_affiliation_strings":["Children\u2019s Hospital of Philadelphia, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Children\u2019s Hospital of Philadelphia, Philadelphia, PA","institution_ids":["https://openalex.org/I1335321130"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5036062620","display_name":"Rochelle Bagatell","orcid":"https://orcid.org/0000-0002-5729-8819","observed_orcids":["https://orcid.org/0000-0002-5729-8819"]},"institutions":[{"id":"https://openalex.org/I1335321130","display_name":"Children's Hospital of Philadelphia","ror":"https://ror.org/01z7r7q48","country_code":"US","type":"funder","lineage":["https://openalex.org/I1335321130"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rochelle Bagatell","raw_affiliation_strings":["Children\u2019s Hospital of Philadelphia, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Children\u2019s Hospital of Philadelphia, Philadelphia, PA","institution_ids":["https://openalex.org/I1335321130"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1335321130"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"34","issue":"21","first_page":"2437","last_page":"2439"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12226","display_name":"Neuroblastoma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12226","display_name":"Neuroblastoma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11173","display_name":"Neurofibromatosis and Schwannoma Cases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/high-risk-neuroblastoma","display_name":"high-risk neuroblastoma","score":0.9860000014305115},{"id":"https://openalex.org/keywords/multimodal-treatment","display_name":"multimodal therapy","score":0.6539999842643738},{"id":"https://openalex.org/keywords/induction-chemotherapy","display_name":"induction chemotherapy","score":0.6000000238418579},{"id":"https://openalex.org/keywords/external-beam-radiotherapy","display_name":"external beam radiotherapy","score":0.7390000224113464},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.6800000071525574},{"id":"https://openalex.org/keywords/anti-gd2-antibody","display_name":"anti-GD2 antibody","score":0.8629999756813049},{"id":"https://openalex.org/keywords/dinutuximab","display_name":"dinutuximab","score":0.9829999804496765},{"id":"https://openalex.org/keywords/isotretinoin","display_name":"isotretinoin","score":0.8209999799728394},{"id":"https://openalex.org/keywords/measurable-residual-disease","display_name":"minimal residual disease","score":0.7390000224113464},{"id":"https://openalex.org/keywords/event-free-survival","display_name":"event-free survival","score":0.7300000190734863},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.875},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.5609999895095825},{"id":"https://openalex.org/keywords/cancer-genomics","display_name":"cancer genomics","score":0.5009999871253967},{"id":"https://openalex.org/keywords/epigenetics","display_name":"epigenetics","score":0.578000009059906},{"id":"https://openalex.org/keywords/proteomics","display_name":"proteomics","score":0.6069999933242798},{"id":"https://openalex.org/keywords/host-factors","display_name":"host factors","score":0.4449999928474426},{"id":"https://openalex.org/keywords/pediatric-oncology","display_name":"pediatric oncology","score":0.42100000381469727}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8870524168014526},{"id":"https://openalex.org/C2776715637","wikidata":"https://www.wikidata.org/wiki/Q938205","display_name":"Neuroblastoma","level":3,"score":0.64143967628479},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.42582252621650696},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.34466010332107544},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D003131","descriptor_name":"Combined Modality Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007223","descriptor_name":"Infant","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009447","descriptor_name":"Neuroblastoma","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.2016.67.2774","doi":"https://doi.org/10.1200/jco.2016.67.2774","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2016.67.2774","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmid:27161969","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27161969","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","raw_type":"Editorial"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":23,"referenced_works":["https://openalex.org/W1508981947","https://openalex.org/W1535107443","https://openalex.org/W1607569714","https://openalex.org/W2003835541","https://openalex.org/W2016440379","https://openalex.org/W2021673773","https://openalex.org/W2032358963","https://openalex.org/W2042363010","https://openalex.org/W2050141946","https://openalex.org/W2067590368","https://openalex.org/W2097120541","https://openalex.org/W2106739013","https://openalex.org/W2108555563","https://openalex.org/W2111733282","https://openalex.org/W2130465135","https://openalex.org/W2131189233","https://openalex.org/W2136574608","https://openalex.org/W2137648684","https://openalex.org/W2147800896","https://openalex.org/W2161798205","https://openalex.org/W2257281028","https://openalex.org/W2341800449","https://openalex.org/W2346745996"],"related_works":["https://openalex.org/W2344763272","https://openalex.org/W2889489530","https://openalex.org/W4283584609","https://openalex.org/W4412750157","https://openalex.org/W2017377546","https://openalex.org/W2895066301","https://openalex.org/W2592112930","https://openalex.org/W4210424404","https://openalex.org/W2998614753","https://openalex.org/W2669798068"],"abstract_inverted_index":{"Treatment":[0],"of":[1,6,13,17,21,44,108,132,155,163,178,207,255,263,350,383,428,441,447,456,464,485,491,505,509,523,544,556,586,606,623,640,647,676,696,706,741],"high-risk":[2,231,298,430,500,549,587,641,648],"neuroblastoma":[3,465,475],"remains":[4,25,60],"one":[5,19],"the":[7,11,66,88,106,133,201,261,278,289,315,332,340,381,438,444,457,461,470,483,489,496,516,542,583,621,645,658,694,739],"major":[8,275],"challenges":[9],"in":[10,87,115,137,143,186,192,215,228,277,295,307,324,339,389,552,651],"field":[12],"pediatric":[14],"oncology.":[15],"Survival":[16],"only":[18,355],"half":[20],"newly":[22],"diagnosed":[23,86,95],"patients":[24,85,94,296,309,365,550,578,598,612,677],"unacceptable,":[26],"and":[27,42,52,98,117,141,158,160,205,223,331,422,460,473,512,565,610,626,632,701,735],"considerable":[28],"efforts":[29],"are":[30,72,591,679],"beingmade":[31],"to":[32,47,53,61,64,91,105,200,245,268,312,321,364,437,482,514,548,575,595,628,633,673,684],"use":[33,490],"tumor":[34,135,203,722],"genomics,":[35],"expression":[36],"profiling,":[37],"epigenetic":[38],"analyses,":[39],"proteomic":[40],"studies,":[41],"analysis":[43],"host":[45],"factors":[46],"better":[48,601],"understand":[49],"this":[50,211,259,398,448,662,742],"malignancy":[51],"develop":[54],"more":[55,680],"effective":[56],"therapies.":[57],"Although":[58,220,401],"much":[59],"be":[62,103,322,671,727],"learned,":[63],"date,":[65,569],"improvements":[67,142],"that":[68,122,173,176,241,265,283,357,541,660,668],"have":[69,80,120,171,242,247,367,477,531],"been":[70,243,435,533,573],"made":[71],"notable,":[73],"as":[74,251,347,603],"5-year":[75],"overall":[76],"survival":[77,145],"(OS)":[78],"rates":[79,140],"increased":[81,390,467],"from":[82,380,397,582,616,686],"29%":[83],"for":[84,93,499],"early":[89],"1990s":[90],"50%":[92],"between":[96,733],"2005":[97],"2010.":[99],"This":[100],"improvement":[101],"can":[102,726],"attributed":[104],"development":[107,262],"modern":[109],"multimodality":[110,451,545],"treatment":[111,511],"regimens.":[112],"Clinical":[113],"trials":[114,240],"Europe":[116],"North":[118,193,236],"America":[119,194],"shown":[121,172],"intensive":[123,221],"multiagent":[124],"induction":[125,222],"chemotherapy":[126,180],"regimens":[127],"combined":[128],"with":[129,181,230,297,326,410,637,688],"surgical":[130],"resection":[131],"primary":[134,202],"result":[136,185,254,349,605],"high":[138],"response":[139],"event-free":[144],"(EFS).":[146],"Children\u2019s":[147,150,303],"Cancer":[148],"Group,":[149,152],"Oncology":[151,157,165,304],"German":[153],"Society":[154,162],"Pediatric":[156,164],"Hematology,":[159],"International":[161],"European":[166,234],"Neuroblastoma":[167],"Research":[168],"Network":[169],"studies":[170,281],"consolidation":[174,190,224,608],"therapies":[175],"consist":[177],"high-dose":[179],"stem":[182],"cell":[183],"rescue":[184],"improved":[187,249,345],"EFS.":[188],"Current":[189],"therapy":[191,225,374,546,609,649,687,709],"also":[195,387],"includes":[196],"external":[197],"beam":[198],"radiation":[199],"bed":[204],"sites":[206],"persistent":[208],"metastatic":[209],"disease;":[210],"strategy":[212,498],"has":[213,434,466,502,571],"resulted":[214],"low":[216],"local":[217],"recurrence":[218],"rates.":[219],"extends":[226],"EFS":[227,361],"children":[229],"disease,":[232],"neither":[233],"nor":[235],"American":[237],"cooperative":[238],"group":[239],"published":[244],"date":[246],"demonstrated":[248,344,478],"OS":[250,391],"a":[252,274,348,479,553,604,654,689],"direct":[253],"these":[256],"interventions.":[257],"In":[258,657,738],"context,":[260],"immunotherapy":[264,359,403,433],"was":[266,273,320],"designed":[267],"address":[269],"minimal":[270],"residual":[271],"disease":[272,370,501],"advancement":[276],"field.":[279],"Early":[280],"indicated":[282],"3F8,":[284],"an":[285,730],"antibody":[286,691,708],"directed":[287],"against":[288,721],"cell-surface":[290],"ganglioside":[291],"GD2,":[292],"showed":[293,356],"promise":[294],"disease.":[299],"A":[300],"landmark":[301],"randomized":[302],"Group":[305],"study":[306],"which":[308,319,577,597,611],"were":[310],"assigned":[311],"receive":[313],"either":[314],"anti-GD2":[316,358],"antibody,":[317],"dinutuximab,":[318],"administered":[323,363],"combination":[325],"granulocyte-macrophage":[327],"colonystimulating":[328],"factor,":[329],"interleukin-2,":[330],"differentiating":[333],"agent":[334],"isotretinoin,":[335],"or":[336,681],"isotretinoin":[337],"alone":[338],"postconsolidation":[341,384,526,618],"setting":[342],"clearly":[343],"outcomes":[346,602],"immunotherapy.":[351],"The":[352,520,704],"trial":[353],"not":[354,368,532,572],"improves":[360],"when":[362],"who":[366,678],"experienced":[369],"progression":[371],"during":[372,469],"initial":[373],"(2-year":[375,392],"EFS,":[376],"66%":[377],"v":[378,395],"46%":[379],"start":[382],"therapy)":[385],"but":[386,536],"results":[388,551],"OS,":[393],"86%":[394],"75%":[396],"time":[399],"point).":[400],"GD2-directed":[402,432,529,690,707],"is":[404,408,538,710],"targeted":[405],"therapy,":[406,431,527,642],"it":[407,537,570,669],"associated":[409,636],"significant":[411],"toxicity.":[412],"Patients":[413],"frequently":[414],"experience":[415,600],"pain,":[416],"allergic":[417],"reactions,":[418],"blood":[419],"pressure":[420],"changes,":[421],"fevers.":[423],"Like":[424],"all":[425],"other":[426],"components":[427,585],"current":[429,524],"added":[436],"existing":[439],"backbone":[440,646],"treatment,":[442],"extending":[443],"total":[445],"duration":[446],"maximally":[449],"intensive,":[450],"therapy.":[452,588,619],"Whereas":[453],"our":[454],"understanding":[455],"genomic":[458],"landscape":[459],"underlying":[462],"biology":[463],"tremendously":[468],"past":[471],"decade,":[472],"although":[474],"investigators":[476],"long-standing":[480],"commitment":[481],"concept":[484],"precision":[486],"medicine":[487],"through":[488,713],"complex":[492],"risk":[493,555],"assessment":[494],"systems,":[495],"therapeutic":[497],"primarily":[503],"consisted":[504],"adding":[506],"on":[507,693],"blocks":[508],"toxic":[510],"attempting":[513],"ameliorate":[515],"accompanying":[517],"adverse":[518,558],"effects.":[519],"late":[521],"effects":[522],"standard":[525],"including":[528,560],"immunotherapy,":[530],"entirely":[534],"elucidated,":[535],"well":[539],"known":[540],"totality":[543],"delivered":[547],"substantial":[554],"treatment-related":[557],"events,":[559],"endocrine":[561],"toxicities,":[562],"hearing":[563],"loss,":[564],"subsequent":[566],"malignancies.":[567],"To":[568],"possible":[574,672],"determine":[576],"will":[579,599,613],"benefit":[580,614,685],"most":[581,615],"various":[584],"Currently,":[589],"there":[590],"no":[592],"reliable":[593],"biomarkers":[594],"indicate":[596],"augmented":[607],"antiGD2\u2013based":[617],"Despite":[620],"desire":[622],"many":[624,652],"clinicians":[625],"families":[627],"maximize":[629],"antineuroblastoma":[630],"activity":[631],"minimize":[634],"toxicity":[635],"each":[638],"portion":[639],"at":[643],"present,":[644],"remains,":[650],"ways,":[653],"package":[655],"deal.":[656],"article":[659],"accompanies":[661],"editorial,":[663],"Forlenza":[664],"et":[665],"al":[666],"show":[667],"may":[670],"identify":[674],"groups":[675],"less":[682],"likely":[683],"(3F8)":[692],"basis":[695],"killer":[697,715],"immunoglobulin-like":[698],"receptor":[699],"(KIR)":[700],"HLA-B":[702],"genotypes.":[703],"effect":[705],"largely":[711],"mediated":[712],"natural":[714],"(NK)":[716],"\u2013directed":[717],"antibody-dependent":[718],"cellular":[719],"cytotoxicity":[720,725],"cells.":[723],"NKmediated":[724],"reduced":[728],"by":[729],"inhibitory":[731],"interaction":[732],"KIR":[734],"HLA":[736],"ligands.":[737],"absence":[740],"inhibition,":[743]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}